Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:administrativeDivision |
biweekly
|
| gptkbp:analyzes |
active
filed |
| gptkbp:barrelLength |
high
|
| gptkbp:clinicalTrials |
ongoing
Phase 1 pending publication multiple sites globally |
| gptkbp:collaborations |
various academic institutions
|
| gptkbp:community_service |
under investigation
overall survival progression-free survival |
| gptkbp:contraindication |
gptkb:melanoma
renal cell carcinoma non-small cell lung cancer monitored during trials |
| gptkbp:currentStatus |
completed
|
| gptkbp:developedBy |
gptkb:Xencor
|
| gptkbp:dosageForm |
every 2 weeks
|
| gptkbp:drugInterdiction |
under study
|
| gptkbp:formulation |
liquid
|
| gptkbp:hasPopulation |
diverse demographics
|
| gptkbp:healthcare |
advanced solid tumors
evaluated in trials |
| gptkbp:historicalResearch |
recombinant DNA technology
exploring combination therapies |
| https://www.w3.org/2000/01/rdf-schema#label |
XmAb®13676
|
| gptkbp:isPortrayedBy |
2016
|
| gptkbp:patentAssignee |
gptkb:Xencor,_Inc.
|
| gptkbp:productionCompany |
in clinical trials
|
| gptkbp:regulatoryCompliance |
not yet approved
|
| gptkbp:relatedTo |
immunotherapy
|
| gptkbp:research |
public and private sources
biopharmaceutical research |
| gptkbp:research_areas |
oncology
immunomodulators |
| gptkbp:researchFocus |
cancer immunotherapy
|
| gptkbp:researchInterest |
improve patient outcomes
with pharmaceutical companies available in scientific journals |
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
under investigation
ongoing during trials |
| gptkbp:sideEffect |
immune-related adverse events
|
| gptkbp:sponsor |
gptkb:Xencor,_Inc.
|
| gptkbp:status |
investigational
|
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
PD-1
patients with advanced cancer |
| gptkbp:triggerType |
immune checkpoint inhibition
blocks PD-1 receptor |
| gptkbp:trimLevels |
with other immunotherapies
|
| gptkbp:usedFor |
cancer treatment
|